A retrospective study to evaluate the effect of Pazopanib and oral cyclophosphamide in women with platinum resistant epithelial ovarian cancers
Latest Information Update: 13 Oct 2017
Price :
$35 *
At a glance
- Drugs Cyclophosphamide (Primary) ; Pazopanib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 13 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress